Genprex

Category: Media Coverage

Note: When you click on media articles below, a new page will open indicating that you are leaving the Genprex, Inc. website and entering a third-party website not affiliated with Genprex Inc. or any of its affiliates. No information contained in a linked site has been endorsed or approved by Genprex, Inc. and Genprex, Inc. is not responsible for the content of such third-party websites.

Can gene therapy be made to work against solid tumours?

As a disease involving mutated genes, cancer has always been a key target for emerging gene therapy technologies.

Read More

Taking gene therapy to the masses with innovations in diabetes, Alzheimer’s and more

What will it take to transition gene therapy from a treatment for diseases that only affect a few hundred thousand people worldwide to Type 1 diabetes, which is estimated to affect more than 45 million?

Read More

2 Austin medical companies expect to raise millions with stock offerings

Two Austin-based companies involved in medial research say they expect to raise millions of dollars with stock offerings this week.

Read More

The Most Studied Research, Most Popular Videos, and Most Read Articles of 2020

What do small cap and micro cap investors look at? We thought you’d want to know what we discovered when we took a look back at Channelchek’s most popular content of 2020.

Read More

The Best (And Worst) Austin Stocks In 2020

And the winners are …

Genprex Inc. (Nasdaq: GNPX), a gene therapy company headquartered in the Texas capital, took the regional title of the year’s largest increase in share value.

Read More

Genprex cancer gene therapy paired with AZ, Merck lung cancer drugs

An experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Co’s Keytruda – both leading their respective drug classes in the treatment of non-small cell lung cancer (NSCLC).

Read More

Genprex to Combine Reqorsa With Checkpoint, EGFR Inhibitors in Lung Cancer Studies

Genprex announced that quaratusugene ozeplasmid (Reqorsa) will be studied in two new trials, in which non-small cell lung cancer patients with specific molecular markers will receive its investigational drug combined with osimertinib (AstraZeneca’s Tagrisso) or pembrolizumab (Merck’s Keytruda).

Read More

Genetic Engineering, No Virus Required

Companies are optimizing nonviral delivery methods for commercial use

Read More

Genprex strikes deal with MD Anderson Cancer Center, adds to momentum in cancer fight

Austin startup a ripe M&A target for big pharma, one expert says

Read More

In pharma, cancer is king

Inside the industry’s quest for its next crowning achievement in oncology.

Read More